Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience

被引：0
|
作者：
Bose, Subhadeep [1 ]
Khaja, Mujtaba Syed [1 ]
Siva, Asha [1 ]
Wilson, Paula [1 ]
Grist, Helen [1 ]
Murukesh, Nishanth [1 ]
机构：
[1] Worcestershire Acute Hosp NHS Trust, Worcester, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21091
引用
收藏
页数：1
相关论文
共 50 条
  • [21] FIRST-LINE COMBINATION THERAPIES FOR ADVANCED RENAL CELL CARCINOMA (ARCC): AN ITALIAN SINGLE-CENTRE REAL-WORLD CLINICAL EXPERIENCE
    Mercinelli, Chiara
    Massaro, Giulia
    Bonato, Adele
    Nuzzo, Amedeo
    Manacorda, Simona
    Sammarco, Enrico
    Manfredi, Fiorella
    Ferrari, Marco
    Salfi, Alessia
    Serafin, Debora
    Zatteri, Luca
    Antonuzzo, Andrea
    Galli, Luca
    ANTICANCER RESEARCH, 2022, 42 (10) : 5144 - 5145
  • [22] First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study
    Provencio-pulla, M.
    Ortega, A. L.
    Coves, J.
    Franco, F.
    Marse, R.
    Domine, M.
    Guirado, M.
    Carcereny, E.
    Fernandez, N.
    Martinez, E.
    Blanco, R.
    Leon, L.
    Sanchez, J. M.
    Sullivan, I.
    Cobo, M.
    Sanchez, A.
    Massuti, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S123 - S124
  • [23] REAL-WORLD USE OF PEMBROLIZUMAB COMBINATION REGIMENS IN FIRST-LINE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Black, Christopher
    Wang, Liya
    Ramakrishnan, Karthik
    Goto, Daisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A832 - A832
  • [24] Real World Experience of First Line Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) at a Tertiary Centre
    Fletcher, J.
    Mullally, W. J.
    Berman, C.
    Ladwa, R.
    Xu, W.
    O'Byrne, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S628 - S629
  • [25] A single centre experience of first-line pembrolizumab in stage IV non-small-cell lung cancer (NSCLC)
    Denslow, R.
    Yarde, A.
    Brunner, C.
    Walther, J.
    Botten, J.
    Jankowska, P.
    LUNG CANCER, 2019, 127 : S35 - S35
  • [26] Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)
    Zakharia, Y.
    Thomaidou, D.
    Li, B.
    Siu, G.
    Levin, R.
    Vlahiotis, A.
    Zanotti, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1423 - S1424
  • [27] Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low
    Attili, I.
    Valenza, C.
    Santoro, C.
    Antonarelli, G.
    Aliaga, P. Trillo
    Del Signore, E.
    Catania, C.
    Spitaleri, G.
    Passaro, A.
    de Marinis, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S51 - S51
  • [28] PERLA: Randomized Phase II Trial of Dostarlimab plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic Non-Squamous NSCLC
    Spira, A.
    Lim, S. M.
    Griesinger, F.
    De Marinis, F.
    Mccarthy, T.
    Huseinovic, N.
    O'Donnell, S.
    Ahn, J. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1013 - S1014
  • [29] Audit of safety and tolerability of combination platinum-pemetrexed-pembrolizumab in advanced non-squamous NSCLC in the real-world setting of a UK Cancer Centre
    Bhalla, N.
    Ghoz, H.
    LUNG CANCER, 2020, 139 : S53 - S54
  • [30] First-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK
    Wang, M.
    Dhokia, P.
    Menon, S.
    Martindale, B.
    ANNALS OF ONCOLOGY, 2018, 29 : 22 - 22
12345